CreatorsPublishersAdvertisers

#Virtual Congress

Generation Bio To Present At European Society Of Gene And Cell Therapy 2021 Annual Virtual Congress

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company's retina therapeutic area.
CAMBRIDGE, MA
targetedonc.com

NCCN Congress: Hematologic Malignancies | Conferences

During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma. Expert Discusses Need for a More Targeted Approach in Acute Myeloid Leukemia. October 15, 2021. In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia,...
CONGRESS & COURTS
Medscape News

Potential First-in-class Drug Shows Disease-Modifying Impact in Atopic Dermatitis

NEW YORK (Reuters Health) - A potential first-in-class anti-OX40 fully human monoclonal antibody has shown promise for treatment of moderate-to-severe atopic dermatitis. In the phase 2 study, all four doses of KHK4083/AMG 451 tested showed statistically greater improvements from baseline in Eczema Area and Severity Index (EASI) score at 16 weeks after subcutaneous administration compared with placebo.
NEW YORK CITY, NY
TRENDING TOPICS
ajmc.com

Ruxolitinib Has Cost-effectiveness, Survival Benefits for Myelofibrosis vs Competitors

Research presented at EHA2021 shows that the JAK 1/2 inhibitor ruxolitinib produced cost-effective benefits per quality-adjusted life-year and increased the overall survival rate for patients with myelofibrosis. A pair of abstracts presented at this year’s European Hematology Association 2021 Virtual Congress (EHA2021) show treatment with Jakafi (ruxolitinib; Novartis) is both...

BioVaxys Announces BVX-0320 Poster Presentation At ISIRV-WHO Virtual Conference

SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in murine model. VANCOUVER, BC, Oct. 8, 2021 /PRNewswire/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTCQB:BVAXF)("BioVaxys" or "Company"), announced today that a poster highlighting its preclinical data on BVX-0320, the Company's SARS-CoV-2 vaccine candidate based on its haptenized viral protein technology, will be presented at a joint Virtual Congress of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) and the World Health Organization (WHO), which is being held October 19-21, 2021.
MEDICAL & BIOTECH
marketscreener.com

Sanofi : New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (Form 6-K)

New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis. *. Low dose arm of the study met the co-primary endpoints of percent change in Eczema Area and Severity Index (EASI) score from baseline, and incidence of treatment-emergent adverse...
MEDICAL & BIOTECH
MedicalXpress

COVID-19 stress may explain new tics in adults

Tics, the repetitive and uncontrollable movements or sounds associated with Tourette syndrome and related disorders, rarely develop out of the blue in adults. But pandemic-related stress could be triggering new tics that emerge suddenly in adults with no prior history of tics, says Caroline Olvera, MD, a movement disorders fellow in the Department of Neurological Sciences at Rush University Medical Center.
MENTAL HEALTH
smanewstoday.com

Neurofilament Blood Levels Likely to Predict Treatment Response in SMA

In infants with spinal muscular atrophy (SMA) type 1, lower blood levels of phosphorylated neurofilament heavy chain (pNF-H) — a marker of nerve cell damage — before starting treatment with Spinraza (nusinersen) are significantly associated with greater motor gains over time. These findings, based on data from the Phase 3...
SCIENCE

AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis

AbbVie Inc (NYSE: ABBV) announced new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating Skyrizi (risankizumab) in adults with active psoriatic arthritis for one year (52 weeks). The results were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress. The new long-term data showed that 70%...
HEALTH
cellandgene.com

A Look Into Cell & Gene: The Podcast Episode 7 Featuring Spark Therapeutics

A few months back, I wrote an article about Hemophilia A and how Spark Therapeutics’ administration of SPK-8011 in patients with hemophilia A resulted in an acceptable safety profile with no deaths and no FVIII inhibitor development with up to 4 years of follow-up. These data reinforce the ability of AAV gene therapy targeting hepatocytes to achieve stable and durable FVIII expression with an acceptable safety profile. A. Spark states that administration of SPK-8011 in patients with hemophilia A resulted in an acceptable safety profile with no deaths and no FVIII inhibitor development with up to 4 years of follow-up. Two of the 17 participants with over one year of data lost FVIII expression due to a presumed cellular immune response to the AAV capsid that was unresponsive to immunosuppression. Indeed, the company recently announced updated data from the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A during the International Society of Thrombosis and Hemostasis (ISTH) 2021 Virtual Congress. Spark retains global commercialization rights to its SPK-FVIII program includes both SPK-8011 and SPK-8016 for hemophilia A. These data demonstrated that administration of SPK-8011 in patients with hemophilia A resulted in sustained factor VIII (FVIII) expression in 16 of 18 participants with up to 4 years of follow-up, as of the May 3, 2021 data cutoff.
HEALTH
marketscreener.com

Dermavant Showcases New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof in Patients with Plaque Psoriasis at the 30th EADV Virtual Congress

- 58.2% of patients who entered the study with a PGA score ≥2 achieved a PGA score of 0 or 1- - Long-term use of tapinarof cream provided improved and durable effects for up to 52 weeks and demonstrated a remittive effect with a median duration of four months for patients entering with a PGA score of 0 -
HEALTH
biospace.com

New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

New, late-breaking data at EADV highlightsemerging clinical profile of amlitelimab(formerly KY1005)in adults with inadequately controlled moderate-to-severe atopic dermatitis. Low dose arm of the study met the co-primary endpoints of percent change in Eczema Area and Severity Index (EASI) score from baseline, and incidence of treatment-emergent adverse events, through week 16.
HEALTH
targetedonc.com

Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment?

Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape. Treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) now includes FDA-approved chimeric...
WAUWATOSA, WI
smanewstoday.com

Spinraza RESPOND Trial Enrolling Children Not Helped by Zolgensma

Biogen is continuing to actively recruit patients for its Phase 4 RESPOND trial, which is evaluating the benefits of Spinraza (nusinersen) in infants and children with spinal muscular atrophy (SMA) who responded poorly to the gene therapy Zolgensma. Participants are now being enrolled at 10 sites in the U.S. and...
HEALTH

Scholar Rock Presents Additional Data Analyses From The Apitegromab TOPAZ Phase 2 Trial At The World Muscle Society 2021 Virtual Congress

Scholar Rock (SRRK) - Get Scholar Rock Holding Corp. Report, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.
MEDICAL & BIOTECH
musculardystrophynews.com

Translarna Preserved Walking 5-plus Years in DMD Boys

Translarna (ataluren) treatment delayed the loss of walking abilities by more than five years in boys with Duchenne muscular dystrophy (DMD) who carry nonsense mutations in their DMD gene, according to a study based on real-world data. The investigational therapy also slowed lung function decline by almost two years. These...
DISEASES & TREATMENTS
YOU MAY ALSO LIKE